Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA500695
Max Phase: Preclinical
Molecular Formula: C43H79NaO12S
Molecular Weight: 821.17
Molecule Type: Small molecule
Associated Items:
ID: ALA500695
Max Phase: Preclinical
Molecular Formula: C43H79NaO12S
Molecular Weight: 821.17
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](CO[C@H]1O[C@H](CS(=O)(=O)[O-])[C@@H](O)[C@H](O)[C@H]1O)OC(=O)CCCCCCCCCCCCCCC.[Na+]
Standard InChI: InChI=1S/C43H80O12S.Na/c1-3-5-7-9-11-13-15-17-18-20-21-23-25-27-29-31-38(44)52-33-36(34-53-43-42(48)41(47)40(46)37(55-43)35-56(49,50)51)54-39(45)32-30-28-26-24-22-19-16-14-12-10-8-6-4-2;/h17-18,36-37,40-43,46-48H,3-16,19-35H2,1-2H3,(H,49,50,51);/q;+1/p-1/b18-17-;/t36-,37-,40-,41+,42-,43+;/m1./s1
Standard InChI Key: OUIMNZABRXUTHM-RGOGCQBZSA-M
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 821.17 | Molecular Weight (Monoisotopic): 820.5370 | AlogP: 8.67 | #Rotatable Bonds: 37 |
Polar Surface Area: 186.12 | Molecular Species: ACID | HBA: 11 | HBD: 4 |
#RO5 Violations: 3 | HBA (Lipinski): 12 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: -1.22 | CX Basic pKa: | CX LogP: 10.47 | CX LogD: 8.09 |
Aromatic Rings: 0 | Heavy Atoms: 56 | QED Weighted: 0.02 | Np Likeness Score: 0.91 |
1. Reshef V, Mizrachi E, Maretzki T, Silberstein C, Loya S, Hizi A, Carmeli S.. (1997) New acylated sulfoglycolipids and digalactolipids and related known glycolipids from cyanobacteria with a potential to inhibit the reverse transcriptase of HIV-1., 60 (12): [PMID:9428159] [10.1021/np970327m] |
2. Loya S, Reshef V, Mizrachi E, Silberstein C, Rachamim Y, Carmeli S, Hizi A.. (1998) The inhibition of the reverse transcriptase of HIV-1 by the natural sulfoglycolipids from cyanobacteria: contribution of different moieties to their high potency., 61 (7): [PMID:9677270] [10.1021/np970585j] |
Source(1):